期刊
TRENDS IN BIOTECHNOLOGY
卷 34, 期 5, 页码 382-393出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2016.01.001
关键词
-
资金
- FEDER (Fundo Europeu de Desenvolvimento Regional) through the Program COMPETE
- Portuguese funds through FCT (Fundacao para a Ciencia e a Tecnologia) [PTDC/SAU-TOX/121887/2010]
- COMPEIE (Project 'Stem Cell Based Platforms for Regenerative and Therapeutic Medicine') [Centro-07-ST24-FEDER-002008]
- FCT [SFRH/BPD/105172/2014]
- Fundação para a Ciência e a Tecnologia [SFRH/BPD/105172/2014, PTDC/SAU-TOX/121887/2010] Funding Source: FCT
The development of novel neuropharmaceuticals requires the evaluation of blood-brain barrier (BBB) permeability and toxicity. Recent studies have highlighted differences in the BBB among different species, with the most important differences involving the expression of P-glycoprotein (P-gp), multi drug resistance-associated proteins, transporters, and claudins. In addition, functional studies have shown that brain pharmacokinetics of P-glycoprotein substrates are different in humans and rodents. Therefore, human BBB models may be an important platform for initial drug screening before in vivo studies. This strategy might help to reduce costs in drug development and failures in clinical studies. We review the differences in the BBB among species, recent advances in the generation of human BBB models, and their applications in drug discovery and delivery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据